Pittsburgh-based UPMC Health Plan has entered into a value-based agreement with drug manufacturer Biogen for two specialty medications used to treat patients with relapsing multiple sclerosis.

Under the agreement, Biogen’s reimbursement to UPMC Health Plan will be linked to any patient-reported progression of disability from MS.

Previous contracts tied payment to such things as hospitalizations, emergency room visits and relapse rates.

The different approach was prompted by a UPMC study in which patients, providers, pharmaceutical manufacturer representatives and others ranked worsening physical disability as one of the most meaningful outcomes of MS.

The two drugs are Tecfidera, which the National Multiple Sclerosis Society says is thought to modulate the immune system’s inflammatory response and may help protect against brain and spinal cord damage, and Avonex, which studies have shown can reduce the risk of a disability progressing.